Tailored Drug Delivery Platform for Reducing Ureteral Fibrosis and Strictures: Bilayer Ureteral Coated StentsCollaborators: Singapore General Hospital (SGH)
Ureteric strictures are an important urological problem that potentially could lead to much morbidity and loss of a functioning kidney. Standard of care comprising endoscopic incision and stenting is not always successful, nor able to produce durable favourable outcomes. We have developed a novel drug delivery platform in the form of a biocompatible coating that may be applied to any regular stent surface. The unique hydrogel coating embedded with drug eluting nanoparticles containing anti-fibrotic drugs would ensure steady and sustained delivery of the drug to the diseased area, thereby reducing stricture recurrence. The treatment is easily terminated when the stent is removed at 6 weeks, as is current clinical practice. We propose to demonstrate the in vitro effects, and the data will provide guidance on further in-vivo testing in large animal models, and ultimately in clinical trials. The technique is simple, cost-effective and readily incorporated into current clinical practice. Additionally, we hope to extend this application to other upper urinary tract pathologies such as tumours within the ureter and renal pelvis.
Funding agencies: SGH Research Grant & MOE – Tier 1